Company: TXG
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001770787-25-000032
Chunk: 340

Company: 10x Genomics, Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part II, Item 1A
Chunk 340
---
 instruments or consumables;

•the success of existing or new competitive businesses or technologies;

•announcements about new research programs or products of our competitors;

•general economic, industry and market conditions;

•volatility and variations in market conditions in the life sciences sector generally, or the genomics sector specifically;

•whether our financial results meet our publicly announced expectations or the expectations of securities analysts or investors;

•actual or anticipated changes in our estimates as to our financial results or development timelines, variations in our financial results or those of companies that are perceived to be similar to us or changes in estimates or recommendations by securities analysts, if any, that cover our Class A common stock or companies that are perceived to be similar to us;

•investor perceptions of us or our industry;

•the level of expenses related to any of our research and development programs or products;

•litigation and governmental investigations involving us, our industry or both;

68

•the outcomes of and related rulings in the litigation and administrative proceedings in which we are currently or may in the future become involved;

•developments or disputes concerning patent applications, issued patents or other proprietary rights;

•the recruitment or departure of key personnel;

•regulatory or legal developments in the United States and other countries;

•the announcement or expectation of additional financing efforts;

•stock-based compensation expense;

•the failure or discontinuation of any of our product development and research programs;

•sales of our Class A common stock or Class B common stock by us, our insiders or other stockholders;

•natural disasters, infectious diseases, conflict, war, civil unrest, epidemics or pandemics or resurgences or major catastrophic events; and

•the other factors described in this “Risk Factors” section.

In recent years, stock markets in general, and the market for life sciences technology companies in particular (including companies in the genomics, biotechnology, diagnostics and related sectors), have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our Class A common stock, regardless of our actual operating performance. Volatility in our stock price also impacts the value of our equity compensation, which affects our ability to recruit and retain employees. In the past, when the market price of a stock has been volatile, securities litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the